These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 16848860)

  • 1. Expressions of cyclin D1, p53, bcl-2, and bax in infiltrative ductal carcinoma of the breast: correlations with clinicopathologic characteristics.
    Arýkök AT; Onal BU; Han U
    Breast J; 2006; 12(4):391-2. PubMed ID: 16848860
    [No Abstract]   [Full Text] [Related]  

  • 2. Alteration of cyclin D1 in Chinese patients with breast carcinoma and its correlation with Ki-67, pRb, and p53.
    Guo LL; Gao P; Wu YG; Jian WC; Hao CY; Li H; Lin XY
    Arch Med Res; 2007 Nov; 38(8):846-52. PubMed ID: 17923265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical evaluation of cyclin D1 in breast cancer.
    Bilalović N; Vranić S; Basić H; Tatarević A; Selak I
    Croat Med J; 2005 Jun; 46(3):382-8. PubMed ID: 15861516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncogenes in male breast cancer.
    Idelevich E; Mozes M; Ben-Baruch N; Huszar M; Kruglikova A; Katsnelson R; Shani A
    Am J Clin Oncol; 2003 Jun; 26(3):259-61. PubMed ID: 12796596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
    Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
    Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between expression of p53/Bcl-2 and histopathological criteria in breast invasive ductal carcinomas.
    Gursan N; Karakök M; Sari I; Gursan MS
    Int J Clin Pract; 2001 Nov; 55(9):589-90. PubMed ID: 11770353
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression of the genes FHIT, Bcl-2 and Bax in breast infiltrating ductal carcinoma and clinicopathological significance thereof].
    Wang ZB; Zhao P; Liu M; Li XH
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(31):2171-6. PubMed ID: 17064501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlations of breast carcinoma biomarkers and p53 tested by FASAY and immunohistochemistry.
    Vagunda V; Smardová J; Vagundová M; Jandáková E; Zaloudík J; Koukalová H
    Pathol Res Pract; 2003; 199(12):795-801. PubMed ID: 14989491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations in survivin expression with the expression of p53 and bcl-2 in invasive ductal carcinoma of the breast.
    Al-Joudi FS; Iskandar ZA; Imran AK
    Southeast Asian J Trop Med Public Health; 2007 Sep; 38(5):904-10. PubMed ID: 18041310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apoptotic markers p53, Bcl-2 and Bax in primary lung cancer.
    Porebska I; Wyrodek E; Kosacka M; Adamiak J; Jankowska R; Harłozińska-Szmyrka A
    In Vivo; 2006; 20(5):599-604. PubMed ID: 17091766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IL-6, its receptors and its relationship with bcl-2 and bax proteins in infiltrating and in situ human breast carcinoma.
    Garcia-Tuñón I; Ricote M; Ruiz A; Fraile B; Paniagua R; Royuela M
    Histopathology; 2005 Jul; 47(1):82-9. PubMed ID: 15982327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
    van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
    Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCL-2, TP53 and BAX protein expression in superficial urothelial bladder carcinoma.
    Gonzalez-Campora R; Davalos-Casanova G; Beato-Moreno A; Garcia-Escudero A; Pareja Megia MJ; Montironi R; Lopez-Beltran A
    Cancer Lett; 2007 Jun; 250(2):292-9. PubMed ID: 17126995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53 overexpression is a predictor of local recurrence after treatment for both in situ and invasive ductal carcinoma of the breast.
    de Roos MA; de Bock GH; de Vries J; van der Vegt B; Wesseling J
    J Surg Res; 2007 Jun; 140(1):109-14. PubMed ID: 17291532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between expressions of telomerase genes and apoptosis related genes in mammary ductal atypical hyperplasia].
    Song M; Li BL; Mi XY; Gao YX; Song JY
    Ai Zheng; 2002 May; 21(5):484-8. PubMed ID: 12452037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cyclin D1 expression in meningiomas: a preliminary study.
    Alama A; Barbieri F; Spaziante R; Bruzzo C; Dadati P; Dorcaratto A; Ravetti JL
    J Clin Neurosci; 2007 Apr; 14(4):355-8. PubMed ID: 17240151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
    Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
    Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of Bax and Bcl-2 expression in p53-immunopositive breast cancers.
    Brambilla E; Negoescu A
    Clin Cancer Res; 1997 Nov; 3(11):2181-3. PubMed ID: 10048937
    [No Abstract]   [Full Text] [Related]  

  • 19. Flow cytometric analysis of apoptosis and bcl-2 in primary breast carcinomas: clinical and biological implications.
    Steck K; McDonnell T; Sneige N; el-Naggar A
    Cytometry; 1996 Jun; 24(2):116-22. PubMed ID: 8725660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-2, bax and p53 expression in rectal adenocarcinoma. Correlation with classic pathologic prognostic factors and patients' outcome.
    Tsamandas AC; Kardamakis D; Petsas T; Zolota V; Vassiliou V; Matatsoris T; Kalofonos H; Vagianos CE; Scopa CD
    In Vivo; 2007; 21(1):113-8. PubMed ID: 17354623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.